Not Signed In - VELCADE(R) For Injection Based Therapies Show Consistently High Complete And Near Complete Response Rates In Front-Line Multiple Myeloma Trials
Wed, 13 Dec 2006 08:00 AM EST
... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results of several clinical trials of VELCADE(R) (bortezomib) for Injection in combination with a variety of agents, including DOXIL(R) (pegylated liposomol doxorubicin) and dexamethasone, for the treatment of newly diagnosed multiple myeloma (MM) patients. [click link for full article] ...
Related Topics
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Thalidomide
- Disaster Response
- Placenta Previa
- Partial or complete arm paralysis
- Partial or complete shoulder paralysis
- Partial or complete loss of sensation in the fingers
- Partial or complete loss of hand movement
- Partial or complete loss of sensation in the arm (uncommon)
- Partial or complete loss of sensation in the arm, hand, or fingers
- Biologically based therapies
- Body-Based Manipulative Therapies
- Multiple myeloma cancer
- Phobias
- Plasma Cell Neoplasm/Multiple Myeloma
- Multiple Myeloma/Plasma Cell Neoplasm
- Multiple Myeloma/Other Plasma Cell Neoplasms
- Dentures
email this page
print this page
bookmark this page
feedback on this page
